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Background
Rheumatoid arthritis (RA) is a chronic autoimmune dis-
ease of the joints, with frequent extra-articular compli-
cations including cardiovascular disease and cardiac
fibrosis from multiple causes. Diffuse myocardial fibrosis
can be detected non-invasively by extracellular volume
(ECV) mapping based on pre- and postcontrast T1 mea-
surements using cardiovascular magnetic resonance
(CMR). We therefore hypothesized that CMR T1 map-
ping can detect subclinical diffuse myocardial fibrosis in
patients with RA.
Methods
39 RA patients (28 female, mean age 50 ± 12 years) and
39 matched controls (28 female, mean age 49 ± 12
years) without previously known cardiovascular disease
underwent CMR at 1.5T. CMR assessments included
late gadolinium enhancement (LGE) [IV gadoterate
meglumine at 0.15 mmol/kg], T1 mapping, cine, tagging,
and T2-weighted imaging.
Results
Focal fibrosis on LGE was found in 18 (46%) RA
patients compared to none of controls. Two of these
patients had evidence of subendocardial enhancement,
in keeping with previously unknown myocardial infarc-
tion. Evidence of diffuse myocardial fibrosis in RA was
supported by higher precontrast T1 values (973 ± 27 vs.
961 ± 18 ms, p = 0.03), lower postcontrast T1 values
(450 ± 40 vs. 468 ± 32 ms, p = 0.04) and expansion of
ECV (30.3 ± 3.4 vs. 27.9 ± 2.0 %, p < 0.001) - the 2 RA
patients with MI were excluded from this analysis.
Indices of diffuse myocardial fibrosis were significantly
elevated in RA, regardless of the presence of LGE.
There was no difference in left ventricular volumes,
mass and ejection fraction between RA patients and
controls. However, there were differences in regional
function: peak systolic circumferential strain (-16.9 ± 1.3
vs. -18.7 ± 1.2, p < 0.001) and peak diastolic strain rate
(83 ± 21 vs. 112 ± 20 s-1, p < 0.001) were impaired in
RA patients. Indices of diffuse myocardial fibrosis corre-
lated with impaired myocardial systolic strain, diastolic
strain rate and RA disease activity. There was no evi-
dence of myocardial edema in RA.
Conclusions
Cardiac involvement is common in RA patients with no
cardiovascular symptoms, and includes both focal and
diffuse myocardial fibrosis, which is associated with
impaired systolic and diastolic strain parameters, as well
RA disease activity. CMR is a robust non-invasive tool
for the assessment of diffuse myocardial fibrosis, and
may be useful in the follow-up of patients. Alterations
in diffuse myocardial fibrosis likely precede significant
changes in cardiac structure and function.
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Female sex, n (%) 28 (72) 28 (72) 1.00
Age, years 49 ± 12 50 ± 12 0.65
Hypertension, n (%) 2 (5) 5 (13) 0.65
Diabetes, n (%) 0 1 (3) -
Hyperlipidaemia, n (%) 5 (13) 6 (15) 0.75
BMI, kg/m2 24 ± 4 26 ± 5 0.13
DAS28-CRP (median, IQR) N/A 3.3 ± 1.3 -
ESR, mm/hr (median, IQR) N/A 15 (9-19) -
CRP, mg/L (median, IQR) 1 (1-2) 9 (4-13) < 0.001
Hemoglobin, g/L 13 ± 1 13 ± 1 0.47
Duration of RA, years (median, IRQ) N/A 7 (4-11) -
Duration of DMARDs, years (median, IQR) N/A 4 (3-6) -
LVEDV indexed to BSA, ml/m2 78 ± 15 80 ± 16 0.63
LVESV indexed to BSA, ml/m2 24 ± 16 23 ± 9 0.62
LVEF, % 73 ± 5 72 ± 7 0.25
LV Mass indexed to BSA, g/m2 52 ± 11 54 ± 12 0.34
LA size, mm 27 ± 5 32 ± 5 < 0.001
Mid SA circumferential strain -19.0 ± 1.2 -17.1 ± 1.2 < 0.001
Peak diastolic circumferential strain rate (s-1) 117 ± 18 85 ± 18 < 0.001
Presence of LGE (%) 0 18 (46) -
Volume fraction of LGE > 2SD (%) 0 3.7 ± 0.4 -
STIR T2 Ratio 1.5 ± 0.1 1.6 ± 0.2 0.07
Continuous data are mean ± SD unless otherwise indicated. BMI, body mass index; CRP, C-reactive protein; DMARD, disease modifying anti-rheumatic drug; ESR,
erythrocyte sedimentation rate; IQR, interquartile range; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular
end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; RA, rheumatoid arthritis; SA, short axis; STIR, short Tau
inversion recovery
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